NEW YORK (GenomeWeb News) – Nanosphere today said that its second-quarter revenues jumped 160 percent year over year, but the firm fell short of Wall Street's estimate for the top line.

The Northbrook, Ill.-based molecular diagnostics firm reported preliminary Q2 revenues of $1.3 million for the three-month period ended June 30, up from $500,000 for the second quarter of 2011. However, it missed analysts' consensus estimate for revenues of $1.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.